N22S (p.Asn22Ser) variant of IRS2 (Insulin receptor substrate 2)
N22S (p.Asn22Ser) in IRS2 (Insulin receptor substrate 2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.24 / 1. The record also includes population frequency data and structural context.
N22S (p.Asn22Ser) variant details
- p.Asn22Ser
- NCI-TCGA Cosmic COSV1010
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.24
- REVEL 0.06
- CADD 16.40
- PolyPhen-2 0.00
- SIFT 0.47
- UniProt: Variant assessed as somatic; moderate impact.
- Population evidence available
- Structural context available